Barclays Upgrades Alexion Pharmaceuticals (ALXN) to Overweight

November 29, 2016 6:42 AM EST
Get Alerts ALXN Hot Sheet
Price: $132.07 +4.82%

Rating Summary:
    21 Buy, 9 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade ALXN Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

(Updated - November 29, 2016 8:15 AM EST)

Barclays upgraded Alexion Pharmaceuticals (NASDAQ: ALXN) from Equalweight to Overweight with a price target of $155.

Analyst Geoff Meacham sees several positives in 2017, including "1) fewer macroeconomic headwinds, 2) restoration of Soliris growth with gMG expansion, 3) pipeline maturation with Soliris in NMO and DGF as well as 1210 moving forward. We don’t view the 10-Q delay and whistleblower investigation as carrying risk of substantial Soliris sales restatement."

For an analyst ratings summary and ratings history on Alexion Pharmaceuticals click here. For more ratings news on Alexion Pharmaceuticals click here.

Shares of Alexion Pharmaceuticals closed at $119.38 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Hot Comments, Hot Upgrades, Upgrades

Related Entities

Barclays

Add Your Comment